The inv(16)(p13q22) chromosomal rearrangement associated with FAB M4Eo acute myeloid leukemia (AML) subtype is characterized by the presence of the CBFbeta/MYH11 fusion transcript that can be used to detect minimal residual disease (MRD). However, qualitative RT-PCR studies of MRD have so far produced conflicting results and seem of limited prognostic value. We have evaluated retrospectively MRD in a large series of CBFbeta/MYH11-positive patients employing both qualitative and quantitative (real-time PCR) approaches. 186 bone marrow samples from 36 patients were examined with a median followup of 27.5 months; 15 patients relapsed during follow-up. In qualitative studies, carried out by 'nested' RT-PCR assay, all patients in complete remission (CR) immediately after induction/consolidation therapy were found to be PCR positive. However, follow-up samples at later time points were persistently negative (except one case) in patients remaining in continuous CR (CCR) for more than 12 months. 16 patients were evaluated by quantitative real-time PCR assay: CBFbeta/MYH11 transcript copy number was normalized for expression of the housekeeping gene ABL, expressed as fusion gene copy number per 10 4 copies of ABL. A 2-3 log decline in leukemic transcript copy number was observed after induction/consolidation therapy. After achieving CR, the mean copy number was significantly higher in patients destined to relapse compared to patients remaining in CCR (151 vs 9, P Ͻ 0.0001 by Mann-Whitney test). Moreover, in CCR patients, the copy number dropped below the detection threshold after the treatment protocol was completed and remained undetectable in subsequent MRD analysis in accordance with results obtained by qualitative RT-PCR. On the contrary, in the seven patients who relapsed, the copy number in CR never declined below the detection threshold; thus a cut-off value discriminating these two groups of patients could be established. The findings of our study, if confirmed, might confer an important predictive value to quantitative real-time PCR determinations of MRD in patients with inv(16) leukemia.
Introduction
Acute myeloid leukemias (AMLs) with translocation t(8;21)(q22;q22) and pericentric inversion of chromosome 16, inv(16)(p13q22) account for about 15% of adult AMLs and share some unique phenotypic and clinical properties. [1] [2] [3] Both types of disease are referred to collectively as core binding factor (CBF) leukemias resulting in the rearrangement, respectively, of alpha (CBFalfa or AML1) or beta (CBFbeta) subunits of the same transcription factor CBF which plays a key role in hematopoiesis. 4 In particular, genomic rearrangements in t (8;21) and inv (16) leukemias fuse CBFalfa with the gene encoding the ETO transcription factor and CBFbeta with the smooth muscle myosin heavy chain gene MYH11, respectively. The resulting hybrid mRNA can be detected by reverse transcriptase polymerase chain reaction (RT-PCR) assay and exploited for both diagnostic and follow-up purposes. 5 Moreover, both leukemia types are usually included in the cytogenetic group of adult AMLs with favorable prognosis with more than 50% of patients obtaining a long-term complete remission (CR). 6 Such favorable results with conventional chemotherapy led some authors to consider that bone marrow transplantation (BMT) is not advisable to consolidate first CR in these patients even when a suitable donor is available. 7 Nevertheless, the high relapse rate still observed in this 'favorable' subgroup of leukemias indicates that reliable methods to detect minimal residual disease (MRD) during hematologic CR are urgently needed in order to better adapt post-remission therapy to specific cohorts of patients.
Unfortunately, the use of qualitative RT-PCR-based methods employed to detect AML1/ETO and CBFbeta/MYH11 fusion genes has not consistently allowed discrimination of prognostic subgroups of CBF AML patients in CR. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Indeed, using highly sensitive two-step conventional RT-PCR assays, most authors found AML1/ETO transcripts in almost all patients in CR, even many years after the end of therapy, when they might reasonably be considered cured of their disease. [11] [12] [13] This latter finding called into question the role of the fusion gene as the unique mutational event involved in the leukemogenesis pathway. 4 In inv(16) AMLs, standard nested RT-PCR studies of MRD have produced conflicting results. While in most reports the large majority of patients in prolonged CR were found to be PCR negative, a few long-term survivors never converted to RT-PCR negativity. [15] [16] [17] Moreover, about 10-20% of PCRnegative patients eventually relapsed suggesting that even the achievement of PCR negativity is not predictive of cure. Some of the difficulty in interpreting the above results may derive from the very limited number of cases studied and from the lack of standardized criteria to establish the presence or absence of the hybrid transcript. 17 Quantitative RT-PCR studies reported to date using both competitive and real-time assays have enabled detection of a decrease in CBFbeta/MYH11 transcript level during early phases of induction and consolidation therapy. However, due to the low number of patients examined, a cut-off level below which cure is likely or above which relapse occurs could not be defined. [18] [19] [20] [21] We carried out a retrospective MRD analysis of a large cohort of AML patients with CBFbeta/MYH11 rearrangements achieving CR after conventional or transplantation therapy: the standard two-step nested RT-PCR was compared with the real-time quantitative PCR assay in order to assess the predictive value of MRD detection in this type of leukemia.
Patients and methods

Patients
Thirty-six AML patients (median age 35 years, range 7-69) with CBFbeta/MYH11 rearrangements diagnosed by RT-PCR were the subject of our study. Patients' characteristics, type of MYH11 molecular breakpoint, treatments and clinical outcome are reported in Table 1 . All patients were treated with standard induction regimens including an anthracycline drug, plus cytarabine and, in most cases, etoposide. Only two patients (Nos 5 and 15) received high-dose ARA-C regimens for remission induction. After achieving CR, all patients underwent a consolidation course consisting in most cases of the same three drugs used for induction. After consolidation, autologous, allogeneic bone marrow transplantation of further conventional chemotherapy were given according to protocols adopted by local institutions. Bone marrow and peripheral blood samples were obtained at diagnosis and during follow-up after informed consent. Due to the retrospective nature of our study, timing of sampling and number of samples collected was not uniform among patients (see Table 1 Clinical and molecular data of patients examined Figure 1 ). However, a mean of five samples per patient were available for RT-PCR analysis. The median follow-up of our patients series was 27.5 months (range 2-77).
Qualitative RT-PCR
One hundred and eighty-six samples were analyzed by qualitative RT-PCR following the protocol designed by the European Biomed Concerted Action. 22 RNA extraction, reverse transcription procedure, amplification conditions, nucleotide sequence and location of primers used to detect different CBFbeta/MYH11 transcripts have been described. 22 The c-ABL housekeeping gene transcript was amplified as an internal control to check the RNA quality of each sample. Following the RT step, a 127 bp size fragment of ABL exons 2-3 was amplified using the following primers: 3Ј antisense (exon 3) 5ЈTGTGATTATGCCTAAGACCCGGAG 3Ј; 5Ј sense (exon 2) 5ЈCTTCTCGCTGGACCCAGTGA 3Ј. Sensitivity testing was carried out by dilution experiments with the inv(16) positive ME-1 cell line (type A breakpoint), using single round PCR experiments a sensitivity of 10 −2 /10 −3 was achieved for In seven out of 103 samples (6.8%) a discrepancy between qualitative and real-time PCR was observed. This was due in some cases to the higher sensitivity of real-time than qualitative PCR. However, in other samples positive by the qualitative method and negative by real-time PCR differential stability of leukemic and housekeeping transcripts might account for the observed results. Amplification reproducibility over time for stored samples is currently under investigation by the European SANCO Concerted Action.
Real-time PCR
Results
Qualitative RT-PCR
A detailed overview of qualitative RT-PCR results is shown in Figure 1 . Overall, bone marrow samples collected at CR after induction or consolidation therapy tested RT-PCR positive regardless of the type of treatment received. However, followup samples of patients who never relapsed converted to PCR negativity between 4 and 12 months after achieving CR, with the exception of only one patient (No. 16) who remained PCR positive, albeit in continuous complete remission (CCR) for 22 months. On the contrary, none of the remission samples of patients who ultimately relapsed tested negative. Considering only patients in CCR, we observed a sharp increase in the percentage of negative samples during follow-up: from 27% in the first 6 months after achieving CR to 69% in the subsequent follow-up period (P Ͻ 0.01 by 2 test). Moreover, all of the seven patients in CCR for more than 2 years with available samples (Nos 3, 4, 5, 7, 11, 13, 22) persistently tested PCR negative, including two patients (Nos 4 and 7), who are long-term survivors with follow-up of 77 and 67 months, respectively.
Real-time PCR
A total of 103 bone marrow samples taken from 16 patients were analyzed by quantitative real-time PCR (Figure 2) . A mean CBFbeta/MYH11/ABL transcript copy number ×10 4 of 13 033 (range 5238-22 109) was detected at diagnosis. No significant difference in the level of fusion gene transcript expression was observed at presentation between patients who relapsed and those who remained in CCR (data not shown). A 2-3 log reduction of the leukemic transcript level was detected after induction/consolidation treatment. Usually a further reduction was obtained following autologous or allogeneic transplantation. More importantly, the amount of leukemic transcript fell below the detection threshold and remained undetectable in further follow-up samples in all patients who persisted in CCR with the sole exception of case 16 ( Figure 2) . On the contrary, a negative real-time PCR status was never observed in CR samples of the seven patients who relapsed, albeit a low level of CBFbeta/MYH11 transcript (1-10 copies) was observed at least once in five of them. Two patients survived and are now disease-free (Nos 12 and 25). In case 12 a negative real-time PCR result was achieved 15 months after reinduction and allogeneic transplantation (data not shown). Overall, considering all bone marrow samples of patients analyzed in first CR (after induction, consolidation and autologous or allogeneic transplant), the mean copy numLeukemia ber of CBFbeta/MYH11 transcripts was higher in CR samples of patients who relapsed (mean 151, range 1-1632) than in CR samples of patients remaining in CCR (mean 9, range 0-133). This difference was highly significant (P Ͻ 0.0001 by Mann-Whitney test). Although a considerable overlap of CR leukemic transcript burden was observed, a cut-off level of one copy of fusion gene transcript/10
4 ABL copies could be established distinguishing patients who relapsed from those remaining in CCR. Indeed, below this threshold level no relapses were observed (Figure 2) . Moreover, after induction, four out of five patients with more than 100 CBFbeta/MYH11 copies/10 4 ABL copies relapsed; whereas, no patient with less than 100 fusion gene copies relapsed. After consolidation, five out of the seven patients with Ͼ10 copies relapsed, whereas only two out of nine patients with Ͻ10 copies relapsed. A significant difference between the two groups persisted at the end of planned treatment (induction, consolidation and autologous or allogeneic transplant): mean 229 copies, range 1-1632 for the group of patients who relapsed vs 5, range 0-50 for patients who never relapsed (P Ͻ 0.03 by MannWhitney test).
Discussion
The actual clinical relevance of monitoring MRD in inv (16) leukemia by RT-PCR is uncertain. In fact most published studies, albeit with a limited number of patients analyzed, reported a high percentage of PCR-positive results in postremission samples, regardless of subsequent clinical outcome, thus precluding a predictive value to RT-PCR results. [15] [16] [17] [18] 24 Our results of qualitative RT-PCR confirm that virtually every patient is PCR-positive in early post remission bone marrow samples. Nevertheless, a gradual decline of MRD down to negativity was observed between 4 and 12 months after CR achievement indicating that even without further chemotherapy, a progressive clearing of residual leukemic cells did indeed occur. A similar trend was observed by other authors 17, 18 thus confirming the presence of, as yet unknown, biologic mechanisms which might contribute to the eradication of residual leukemic cells, even in a 'nonallotransplant' setting. Moreover, in the present series longterm survivors in CCR ultimately tested PCR negative, suggesting that 'cure' of inv (16) leukemia is strictly associated with a persistent PCR negativity. This observation is apparently in sharp contrast with the findings reported in t(8;21) leukemia, where long-term CCR is usually associated with persistence of MRD. [11] [12] [13] However, more recent studies using stringent quality control criteria for RT-PCR amplification, indicate that, even in t(8;21) leukemia, achievement of PCR negativity, at this level of sensitivity, is crucial to maintain CCR. 14 A limited number of studies have so far addressed the quantitation of CBFbeta/MYH11 transcripts in inv(16) leukemia at diagnosis and during follow-up. [18] [19] [20] [21] Both competitive and real-time amplification technologies were employed in small patient series analyzed retrospectively. In our study of 16 patients, also analyzed retrospectively, we observed a dramatic decrease (2-3 log) of the leukemic transcript level after induction/consolidation treatment with further reduction after autologous or allogeneic transplant. Most patients (14/16) achieved a reduction in CBFbeta/MYH11 fusion transcripts to less than 10 copies/10 4 ABL copies by the end of the planned treatment in at least one bone marrow sample (Figure 2) . Notably, considering samples of all patients analyzed in first complete remission, a highly significant difference was Quantitation of CBFbetaMYH11/ABL transcript copy number over time. Red lines indicate patients who relapsed, green lines patients in CCR. Numbers in closed circles identify each patient analyzed (see also Figure 1 and Table 1 ). R, relapse. Blue dotted line indicates threshold level of leukemic transcript (see text for details).
observed in the mean transcript copy number of patients who relapsed, as compared to those remaining in CCR. More importantly, in spite of a considerable overlap between these two patient groups, a threshold level of CBFbeta/MYH11 transcripts could be established to distinguish the two cohorts ( Figure 2) . In fact, patients who never relapsed fell below the level of one copy of leukemic transcript/10 4 ABL copies (ie they became PCR negative). Only patient (No. 16) did not comply with this rule, still displaying a detectable, although low level of transcript (3 copies/10 4 ABL copies) 20 months after diagnosis. Further observation on prolonged follow-up will clarify if late clearance of the residual leukemic cells or disease relapse will occur in this case. While fusion gene transcript level at diagnosis was not predictive of subsequent outcome, the level at later time points identified patients at high and low risk of relapse (threshold values: 100 copies/10 4 ABL copies after induction and 10 copies/10 4 ABL copies after consolidation therapy). Furthermore, in our series negative PCR status, using the qualitative assay, was strongly associated with prolonged CR in keeping with the results obtained by real-time amplification. Overall, our findings are in agreement with those recently published using quantitative RT-PCR in inv(16) leukemia. 18, 20, 21 One patient in the report from Laczika et al 19 and three patients in the Krauter et al 20 study relapsed and none of them had converted to a level of transcript below the detection threshold. Moreover, the seven patients that in both studies never relapsed, obtained PCR negativity between 3 and 16 months after treatment. 19, 20 In the larger series reported by Marcucci et al, 21 no difference in the level of CBFbeta/MYH11 transcript was observed, in the early phase of CR, between patients who relapsed and those remaining in CCR; however, at the end of the planned chemotherapeutic program, a cut-off copy number Ͼ10 was found to discriminate patients with high and low risk of relapse. Thus, in the above studies, as well as in ours, the degree of reduction of leukemic transcript was predictive of clinical outcome. This represents an important achievement from the clinical point of view as it may allow treatment intensification during CR in order to prevent relapse in high risk patients. In conclusion, we believe that if the above results could be confirmed in prospective studies with uniform timepoint sampling, quantitative RT-PCR analysis should be added to the 'routine' clinical armamentarium employed in clinical decision-making of inv(16) myeloid leukemia. In the meantime, available data suggest that serial bone marrow real-time determinations (ie after induction, consolidation and at the end of treatment program) could be already of predictive value during the follow-up of patients in CR.
